Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

TAK-491

Known as: TAK 491, TAK491 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Azilsartan medoxomil potassium salt (TAK-491) is an orally administered angiotensin II type 1 receptor blocker for the treatment… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2013
2013
The absorption process in animals of TAK-491, designed as ester-based prodrug with medoxomil moiety, was evaluated. In the plasma… Expand
2011
2011
Increased expression of plasminogen activator inhibitor type-I (PAI-1) in vessel walls seems to accelerate atherosclerosis… Expand
Review
2011
Review
2011
BACKGROUND Azilsartan medoxomil is an angiotensin receptor blocker, approved on February 25, 2011 by the US Food and Drug… Expand
Review
2011
Review
2011
Objective: To evaluate the efficacy, safety, and clinical role of azilsartan medoxomil, an angiotensin II receptor blocker (ARB… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
2010
2010
PurposeWe assessed the effects of TAK-491 (a newly designed potent and selective ARB) alone and in combination with pioglitazone… Expand
  • table 1
  • figure 1
  • figure 3
  • figure 2
  • figure 4